6-Isopropyl-6-nor-lysergic acid diethylamide

6-Isopropyl-6-nor-lysergic acid diethylamide

Clinical data
Routes of administration	Oral
Legal status
Legal status	US: Analogue to a Schedule I/II drug (but only if it is intended for human consumption)
Identifiers
IUPAC name (8β)-N,N-Diethyl-6-isopropyl-9,10-didehydroergoline-8-carboxamide
(verify)

IP-LAD, known also as 6-isopropyl-6-nor-lysergic acid diethylamide, is an analogue of LAD developed by the team of David E. Nicols. In studies on mice, it was found to be approximately 40% the potency of LAD, compared to the 60% increase in potency seen with ETH-LAD and roughly equivalent potency in AL-LAD and PRO-LAD.

References

Hoffman, A. J.; Nichols, D. E. (1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID 4032428.